Skip to main content
. Author manuscript; available in PMC: 2020 Jul 13.
Published in final edited form as: Mol Pharm. 2019 Jan 16;16(2):552–560. doi: 10.1021/acs.molpharmaceut.8b00836

Table 1.

Cell Cytotoxicity of Paclitaxel and Rapamycin Individually and in Combination

cell type ES-2-luc human ovarian cancer ES-2-luc ascites mouse ovarian cancer ES-2-luc-PTXtreated ascites mouse ovarian cancer
IC50 of paclitaxel (nM) 119.2 136.5 193.9
IC50 of rapamycin (nM) 647.8 549.0 482.9
IC50 of paclitaxel/ rapamycin (nM) 130.3 53.6 65.5
combination index 0.6473 0.2451 0.2368